Tamoxifen
Tamoxifen is a hormonal therapy for estrogen receptor-positive breast cancer, used after surgery to lower the chance of recurrence, for advanced disease, and to reduce breast cancer risk in women at high risk. It works largely through endoxifen, an active metabolite that the liver enzyme CYP2D6 makes, and people with little or no CYP2D6 activity have much lower endoxifen levels [1]. For poor metabolizers taking tamoxifen after surgery, the Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends an alternative such as an aromatase inhibitor. For intermediate metabolizers it advises considering one [2]. The FDA label says the effect of CYP2D6 on efficacy is not well established [1].
| Brand names | Soltamox (oral solution); generic tablets. The original brand, Nolvadex, is listed as discontinued in the FDA's Drugs@FDA database. |
|---|---|
| Used for | Estrogen receptor-positive breast cancer: treatment after surgery (adjuvant) and of metastatic disease; reducing the risk of invasive breast cancer after DCIS and in women at high risk |
| Genes | CYP2D6 |
| Guidance | CPIC guideline (2018), level A [2]; DPWG [3]; FDA label (section 12.5) [1] |
| Gene2Rx coverage | Consumer DNA tests and whole-genome sequencing. |
How tamoxifen works
Tamoxifen blocks the estrogen receptor in breast tissue, so estrogen cannot drive the growth of receptor-positive cancer cells. In other tissues it can act like a weak estrogen [2]. CPIC notes that 5 years of tamoxifen after surgery for estrogen receptor-positive breast cancer almost halves the yearly recurrence rate and cuts breast cancer deaths by about a third [2]. The usual dose is 20 mg a day; after surgery it is taken for 5 to 10 years, and for advanced disease the label allows 20 to 40 mg a day [1].
Tamoxifen is partly a prodrug. Most of each dose (CPIC estimates over 90%) is first converted by CYP3A4 to N-desmethyltamoxifen, and CYP2D6 then turns that into endoxifen. A smaller pathway, also mainly CYP2D6, makes 4-hydroxytamoxifen [2]. Endoxifen and 4-hydroxytamoxifen bind the estrogen receptor about 100 times more strongly than tamoxifen. Endoxifen circulates at levels up to 10 times those of 4-hydroxytamoxifen [1][2].
- Tamoxifenweak at the receptor
- N-desmethyltamoxifenmade mainly by CYP3A4
- Endoxifenmade by CYP2D6; about 100 times more potent
Tamoxifen has a long half-life of 5 to 7 days and takes about 4 weeks to reach steady levels [1]. The label carries a boxed warning about uterine cancers, stroke and pulmonary embolism. It asks prescribers to discuss these risks with women considering tamoxifen to reduce breast cancer risk, and states that for most people already diagnosed with breast cancer the benefits outweigh the risks [1].
How CYP2D6 affects tamoxifen
CYP2D6 is one of the most variable drug-metabolizing genes. Each version (star allele) has a function, and the two copies a person carries are combined into an activity score that sets the metabolizer group [2]. The codeine page explains the scoring, and the metoprolol page shows how common each group is by population.
Endoxifen levels
The link between CYP2D6 and endoxifen is well established. In the Women's Health Eating and Living study, cited in the Soltamox label, mean endoxifen levels were 22.8 ng/mL in 27 ultrarapid metabolizers, 15.9 in 1,097 normal metabolizers, 8.1 in 164 intermediate metabolizers and 5.6 in 82 poor metabolizers [1]. CPIC rated the evidence that poor metabolizers, and people with reduced CYP2D6 activity in general, have lower endoxifen as strong, and notes that CYP2D6 genotype explains 34 to 52% of the variation in endoxifen levels [2].
Breast cancer outcomes
Whether lower endoxifen leads to more recurrences is the contested part. Early studies found that poor metabolizers had about two to three times the risk of recurrence of normal metabolizers. Later analyses of large trials, including ATAC, BIG 1-98 and ABCSG 8, did not confirm it, and a meta-analysis found an association with disease-free survival only in patients who took 20 mg a day for five years after surgery. Two studies linked low endoxifen levels themselves with recurrence [2]. CPIC graded the evidence that poor metabolizers have a higher risk of recurrence or worse event-free survival as moderate, and the evidence for the other groups and endpoints as weak [2]. The FDA label states that the effect of CYP2D6 on efficacy is not well established [1], and the FDA lists tamoxifen in Section 3 of its Table of Pharmacogenetic Associations, for effects on drug levels only [4].
Activity score 1 and the *10 allele
The 2018 guideline left people with an activity score of 1.0 (for example *1/*4 or *41/*41) labeled "normal or intermediate metabolizer", because they make less endoxifen than people scoring 1.5 or 2. Its recommendation for that group is "moderate" when the score comes from the *10 allele, common in East Asian populations, and "optional" otherwise, since the evidence comes mostly from *10 carriers [2]. In 2020, CPIC and the DPWG agreed to call an activity score of 1.0 an intermediate metabolizer, and lowered the value of the *10 allele to 0.25 [5]. A Gene2Rx intermediate metabolizer result can therefore cover people whom the 2018 guideline would rate at either strength.
What the guidelines recommend
CPIC published its tamoxifen guideline in 2018 and rates the pair level A [6], its highest level: genetic information should be used to change prescribing [7]. The recommendations apply to tamoxifen given after surgery for estrogen receptor-positive breast cancer, the setting the evidence comes from; they do not cover prevention, DCIS or metastatic disease [2]. The aromatase inhibitor alternatives are written for women: on their own after menopause, or combined with ovarian function suppression before menopause. CPIC bases them on two points: these approaches are superior to tamoxifen whatever the CYP2D6 genotype, and poor metabolizers who switched from tamoxifen to anastrozole did not have a higher recurrence risk [2].
| Result | What it means | Guideline recommendation |
|---|---|---|
| Ultrarapid Metabolizer | Therapeutic endoxifen levels expected. This result requires extra gene copies. | CPIC: standard dosing (20 mg a day); avoid moderate and strong CYP2D6 inhibitors (strong). |
| Normal Metabolizer | Therapeutic endoxifen levels expected. | CPIC: standard dosing (20 mg a day); avoid moderate and strong CYP2D6 inhibitors (strong). |
| Intermediate Metabolizer | Lower endoxifen levels than normal metabolizers, and a higher risk of recurrence and worse event-free and recurrence-free survival. | CPIC: consider an aromatase inhibitor (with ovarian function suppression before menopause). If one cannot be used, consider the higher FDA-approved dose of 40 mg a day. Avoid strong, moderate and weak CYP2D6 inhibitors (moderate; optional for some activity scores of 1.0). |
| Poor Metabolizer | Lower endoxifen levels than normal metabolizers, and a higher risk of recurrence and worse event-free and recurrence-free survival. | CPIC: recommend an alternative such as an aromatase inhibitor (with ovarian function suppression before menopause). 40 mg a day raises endoxifen but does not bring it to normal, and can be considered if an aromatase inhibitor cannot be used (strong). |
| Indeterminate or not available | The alleles found could not be assigned a function, or no CYP2D6 result was available. | CPIC makes no recommendation. The report notes the usual starting dose. |
The Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association (DPWG) reaches similar conclusions in its current guidance. For poor metabolizers it advises choosing an alternative or raising the dose to 40 mg a day and monitoring endoxifen. For intermediate metabolizers it advises an alternative, or measuring endoxifen and raising the dose 1.5 to 2 times if needed, while avoiding CYP2D6 inhibitors such as paroxetine and fluoxetine. It names aromatase inhibitors as a possible alternative after menopause, and advises no action for ultrarapid metabolizers [3].
Want to know what your genetics say about how you'll respond to Tamoxifen?
A Gene2Rx report reads your own DNA to show how it may affect your response to Tamoxifen and your other medications.
Using your result
A CYP2D6 result is most useful before endocrine therapy is chosen, so share it with your oncologist early. The choice between tamoxifen and an aromatase inhibitor also depends on menopausal status and the tumor's features, and CPIC calls CYP2D6 one of several pieces of information to weigh [2]. Do not stop or change tamoxifen because of a genetic result without talking to your oncologist.
Antidepressants and other CYP2D6 inhibitors
This matters for everyone on tamoxifen, whatever their genotype. Some antidepressants strongly block CYP2D6. In the Soltamox label, normal metabolizers taking potent CYP2D6 inhibitors such as paroxetine or fluoxetine had endoxifen levels of 8.8 ng/mL, compared with 31.4 ng/mL in normal metabolizers not taking them, and close to the 7.2 ng/mL seen in poor metabolizers [1]. The label adds that the effect of strong CYP2D6 inhibitors on tamoxifen's efficacy is not well established, since studies disagree. CPIC advises avoiding prolonged overlap with strong and moderate inhibitors, and also weak ones in intermediate metabolizers [2]. The FDA lists bupropion, quinidine and terbinafine as other strong inhibitors, and duloxetine among the moderate ones [8]. If you take or need one of these medicines, ask your prescriber whether an alternative that does not block CYP2D6 would suit you.
Other genes matter less. CPIC reviewed CYP2C9, CYP3A4, CYP3A5 and CYP2C19 and found small or inconsistent effects, with no recommendation [2]. Strong CYP3A4 inducers such as rifampin cut tamoxifen exposure by 86% [1].
What this result cannot tell you
Consumer arrays (23andMe, AncestryDNA, MyHeritage) are not clinical-grade tests, and their raw data is labeled not for medical use. They read fixed positions, and Gene2Rx uses imputation to infer some variants that were not measured directly. A normal result means none of the assessed variants was found among the positions your data covers; it cannot rule out a variant the data does not cover. CPIC notes that rare variants missed by a test leave an allele called *1 by default [2]. Because the choice of endocrine therapy is a high-stakes, long-term decision, a clinical CYP2D6 test is reasonable before acting on a result. CPIC also advises testing blood or saliva rather than tumor tissue, whose DNA can differ [2].
A genotype says nothing about the cancer itself. CPIC notes that tumor features such as estrogen receptor, progesterone receptor and HER2 status drive the response to endocrine therapy, and that reduced CYP2D6 activity may matter differently in early, low-risk cancer than in later-stage disease [2].
Common questions
I am a poor metabolizer and already on tamoxifen. Has it been working?
A genotype cannot answer that. Poor metabolizers make less endoxifen, and some but not all studies link that to more recurrences (see How CYP2D6 affects tamoxifen). Ask your oncologist whether switching or a higher dose makes sense for you.
Can a higher tamoxifen dose make up for it?
Partly. CPIC notes that 40 mg a day raises endoxifen in poor metabolizers but does not bring it to normal levels, so it is a fallback when an aromatase inhibitor cannot be used [2].
Does this apply to men?
The Soltamox label's breast cancer indications cover adult patients, not only women [1]. CPIC's alternatives are written for women before and after menopause, so for men the choice is one for the oncologist.
Sources and further reading
- Soltamox (tamoxifen citrate) oral solution: prescribing information (Mayne Pharma). DailyMed. Indications, dosing, boxed warning, metabolism, CYP2D6 pharmacogenomics and inhibitor data.
- Goetz MP et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther (2018). CPIC recommendations, evidence on endoxifen and outcomes, activity score 1.0, testing caveats.
- ClinPGx. Annotation of DPWG clinical guideline for tamoxifen and CYP2D6. Current DPWG recommendations.
- FDA. Table of Pharmacogenetic Associations. Tamoxifen entry (Section 3).
- Caudle KE et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci (2020). Reclassification of activity score 1.0 and of *10.
- CPIC. Gene-drug pairs and CPIC levels (spreadsheet). Level A for CYP2D6 and tamoxifen.
- CPIC. Assignment of CPIC levels for genes/drugs (ClinPGx). What each CPIC level means.
- FDA. For healthcare professionals: FDA's examples of drugs that interact with CYP enzymes and transporter systems. Strong and moderate CYP2D6 inhibitors.
Genes that affect Tamoxifen
See the full list of drugs affected by each gene:
Brand names containing Tamoxifen
See how your genetics affect each product Tamoxifen shows up in:
Related guides
Learn more about how genetics may affect your response to Tamoxifen and related medications:
- 23andMe Pharmacogenetics: How to Get a Drug Response Report From Your Existing Data
- AncestryDNA for Drug Testing: Get Pharmacogenetics From Your Ancestry Data
- Can Two Safe Medications Be Dangerous Together? How Metabolism Interactions Work
- CYP2D6 Structural Variants: Deletions, Duplications and Gene Fusions Explained
- Genera Pharmacogenetics: Turn Your Genera Raw Data Into a Drug Response Report
- Looking for a GeneSight Alternative? Here's the Short Answer
- Medications That Cause Phenoconversion: The Common Enzyme Inhibitors
- MyHeritage Pharmacogenetics: Use Your MyHeritage DNA for a Drug Response Report
- Nebula Genomics Pharmacogenetics: How to Get a Drug Response Report From Your WGS Data
- How Much Does a Pharmacogenetic Test Cost? 2026 Prices and Cheaper Alternatives
- Tamoxifen Not Working? Why Genetics Matters for Breast Cancer Treatment
- TellMeGen Pharmacogenetics: Turn Your TellMeGen Raw Data Into a Drug Response Report
- How to Read Your GeneSight Report: Green, Yellow, and Red Explained
- What Is Phenoconversion? When Your Medications Override Your Genes
- Whole Genome Sequencing for Pharmacogenetics: A Complete Guide
Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.
I'm Interested